Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon and University of Leicester Form CoE in rAAV-mediated Genome Editing

Published: Monday, July 16, 2012
Last Updated: Monday, July 16, 2012
Bookmark and Share
Collaboration will focus on developing isogenic models of cardiovascular disease.

Horizon Discovery (Horizon) has announced that it has established a Center of Excellence (CoE) for gene editing at the University of Leicester, UK.

The program will focus on the creation of isogenic cell lines that contain ‘risk’ or ‘protective’ SNPs associated with cardiovascular disease, identified from GWAS studies.

Horizon’s CoE program encompasses academic and not-for-profit research groups or laboratories to which Horizon commits resources to provide training and open access to its proprietary rAAV-mediated human gene-editing platform, GENESIS™.

The University of Leicester is the first of Horizon’s Centers of Excellence to focus on cardiovascular disease.

The new human isogenic cell lines generated by the University of Leicester will be exclusively licensed to Horizon in return for future product royalties.

Horizon will also have an exclusive option to license new intellectual property developed.

This forms part of Horizon’s strategy to generate at least 2500 new X-MAN™ (gene X- Mutant And Normal) models of cancer, neurodegenerative, and cardiovascular disease.

These models support drug discovery researchers in their efforts to understand how complex genetic diseases manifest themselves in real patients, and help rationalize many aspects of drug development, reducing the cost of bringing to market new personalized therapies.

“Horizon’s rAAV-mediated genome editing can fundamentally alter the genome of cells, leading to the creation of patient-relevant disease models. The use of these models in oncology is well established, and has predicted patient responses to targeted therapies both during drug development and in the clinic,” commented Dr Rob Howes, Principal Scientist, Horizon Discovery.

Dr Howes continued, “By developing the application of this technology to other disease areas such as cardiovascular disease, we aim to lead the development of personalized medicines in these areas.”

Prof Nilesh Samani, British Heart Foundation Professor of Cardiology and Head of Department of Cardiovascular Sciences at the University of Leicester, commented: “The opportunity to apply Horizon’s GENESIS technology for development of cardiovascular disease cell lines offers an exciting progression in the study of the disease. We look forward to working with Horizon on this program.”

Dr Tom Webb, British Heart Foundation Lecturer in Cardiovascular Genomics, at the University of Leicester, said: “We are delighted to have this partnership with Horizon. By using rAAV-mediated genome editing we can create cell models to investigate how specific genetic variants contribute to the development of cardiovascular disease.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Announces Oncology Drug Discovery Collaboration with AstraZeneca
Agreement to explore Horizon’s first-in-class kinase target programme, HD-001.
Monday, April 22, 2013
Horizon and Domainex Collaborate to Support Lead Optimization Oncology Program
Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds.
Tuesday, August 07, 2012
Horizon and H3 Biomedicine to Collaborate
H3 Biomedicine to employ Horizon’s unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics.
Friday, May 04, 2012
Horizon Announces Strategic Partnership with Promega
Partnership to combine Horizon’s genome editing technology with Promega’s reporter technologies to enable personalized drug development.
Tuesday, November 08, 2011
University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
The collaboration will identify and validate novel cancer targets and biomarkers for personalized cancer therapy and diagnostics.
Monday, October 19, 2009
Horizon Discovery Sign Commercial Screening Agreement with Silicos
Agreement covers testing of Silicos lead compounds on human isogenic cell-lines comprising specific genotypes targeted by the compound series.
Tuesday, August 25, 2009
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
License relates to the use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patients.
Tuesday, August 11, 2009
Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals
The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.
Thursday, December 18, 2008
The X-MAN Steps-Out: Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
Horizon Discovery (Horizon) today announced it has signed two commercial agreements with a ground-breaking U.S. cancer start-up; Agios Pharmaceuticals (Agios), relating to its X-MAN technology.
Wednesday, October 01, 2008
Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
The agreements cover the licensing of certain X-MAN cell lines and the screening of a number of Agios lead compounds on a wide panel of genotypes.
Wednesday, October 01, 2008
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos